EDX Medical Group

EDX Medical Group EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EDX Medical Group (EDX.AQ) as of Nov 3, 2026 is -3.96 M GBP. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.06 M GBP — a change of 29.39% (lower).

EBITDA

-3.96 MGBP

YoY

29.39%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EDX Medical Group is 2025 -3.96 M GBP. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EDX Medical Group was 2024 -3.06 M GBP. It decreases by 29.39% lower compared to the previous year.

The EDX Medical Group EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
-11,200.00 GBP
Jan 1, 2022
-253,400.00 GBP
Jan 1, 2023
-2.58 M GBP
Jan 1, 2024
-3.06 M GBP
Jan 1, 2025
-3.96 M GBP
The EDX Medical Group EBITDA history
YEAREBITDAYoY
-3.96 MGBP+29.39%
-3.06 MGBP+18.72%
-2.58 MGBP+918.31%
-253,400.00GBP+2,162.50%
-11,200.00GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EDX Medical Group Stock analysis

What does EDX Medical Group do? EDX Medical Group Plc generates revenue through the sale of digitally enabled diagnostic products and services to individuals and organizations. The company offers point-of-care, home, and workplace testing tools that allow personalized diagnosis according to international standards. Its disease surveillance solutions are sold to cross-border agencies and governments for identifying new disease variants with high transmission risks. The firm also partners with researchers and clinicians to commercialize their discoveries into marketable products. The primary buyers of EDX Medical Group's diagnostic tools include healthcare professionals, individuals seeking personal health monitoring, and government agencies responsible for public health surveillance. Cross-border agencies utilize the disease surveillance solutions to track rapidly spreading variants. Researchers and clinicians form strategic partnerships to develop and launch new diagnostic products through the company's platform. EDX Medical Group's product portfolio consists of diagnostic tests for point-of-care, home, and workplace use, alongside disease surveillance systems. The company's services focus on enabling personalized medical diagnosis and early detection of disease variants. Revenue streams are derived from direct sales of diagnostic tools, government contracts for surveillance systems, and partnership agreements with research institutions. EDX Medical Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EDX Medical Group stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EDX Medical Group is -3.96 M GBP in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EDX Medical Group changed from -3.06 M GBP to -3.96 M GBP, representing a 29.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) EDX Medical Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EDX Medical Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — EDX Medical Group

All Key Metrics — EDX Medical Group